Introductory Company Profile
Poster from WVIC SF 2019
SeromYx Systems is excited to join the 12th World Clinical Biomarkers & CDx Summit in #Boston this September 28-29, at the industry’s definitive end-to-end biomarker-driven and diagnostic-enabled drug development meeting. At our booth learn about how we can help you with developing diagnostic or prognostic insights using high-throughput conduct of a comprehensive set of antibody effector function assays and machine learning analytics.
SeromYx is proud to introduce our new location at 299D Washington Street in Woburn, MA. Both our business and lab operations are based out of this brand-new custom 8,000 sq. ft facility, with space to continue our growth and further enhancing our capabilities to provide our customers with high-throughput GCLP certified Systems Serology services.
SeromYx Systems to present at World Vaccine & Immunotherapy 30- Nov – 2 Dec 2021, Loews Coronado Bay Resort, San Diego. Dr. Todd Suscovich, SeromYx’s Chief Technical Officer will be presenting on how data from Systems Serology studies guided the development of mAb therapies for CoV2.
World Vaccine & Immunotherapy
Nov 30 – Dec 2, 2021
SeromYx Systems participates at the Immuno-Oncology Summit, Westin Copley Place, Boston. Kaustuv Banerjee, Director, Scientific Development will be talking to participants with the objective of understanding how Systems Serology could benefit Oncology programs.
Oct 4-5, 2021
Founder Galit Alter featured as one of the Boston Globe’s 2020 Bostonians of the Year
Boston Globe Dec 13 2020
Identify the mechanistic immune markers associated with natural infection (disease outcome), vaccination, or treatment.
Screening therapeutic monoclonal antibodies for desired function.
Development of vaccine design strategies (e.g., prime/boost, dose and timing (e.g., delayed fractional dose), adjuvants)
Assay Development, Qualification, Validation
Which assays need to be demonstrated to be statistically robust so that data from them can be included in regulatory filings?
What product construct best delivers the desired mix of function?
Does antibody process development affect its functional profile?